Startup profile · funding coverage
Enveda funding, valuation and investors
AI drug discovery built on nature's chemistry.
Keep track of Enveda
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series E
$311M · September 23, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$311M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Boulder, Colorado
Investors in latest funding
Lead: Catalio Capital Management
Other: Durable Capital Partners , ICONIQ , Lightspeed , Surveyor Capital
Overview
Clinical-stage biotechnology company using machine learning and natural-product chemistry to identify drug candidates from biological sources.
Why Enveda is interesting
Enveda links large-scale biological data and AI with a clinical pipeline, making its execution measurable through trial progress rather than discovery claims alone.
Funding history (newest first)
Series E
2026-09-23 $311M- Catalio Capital Management (lead)
- Durable Capital Partners (participant)
- ICONIQ (participant)
- Lightspeed (participant)
- Surveyor Capital (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.